BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamashita M, Wada H, Eguchi H, Ogawa H, Yamada D, Noda T, Asaoka T, Kawamoto K, Gotoh K, Umeshita K, Doki Y, Mori M. A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma. Int J Oncol. 2016;49:89-98. [PMID: 27121124 DOI: 10.3892/ijo.2016.3496] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Brunelli M, Erdini F, Cima L, Eccher A, Fioravanzo A, Gobbo S, Segala D, Ghimenton C, Mazzoleni G, Munari E, Carella R, Martignoni G. Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification. Appl Immunohistochem Mol Morphol 2018;26:316-23. [PMID: 27556823 DOI: 10.1097/PAI.0000000000000435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
2 He X, Xu Y, Shi W, Ma H. Ultrasensitive Detection of Aminopeptidase N Activity in Urine and Cells with a Ratiometric Fluorescence Probe. Anal Chem 2017;89:3217-21. [DOI: 10.1021/acs.analchem.7b00021] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
3 Han L, Zhang Y, Liu S, Zhao Q, Liang X, Ma Z, Gupta PK, Zhao M, Wang A. Autophagy flux inhibition, G2/M cell cycle arrest and apoptosis induction by ubenimex in glioma cell lines. Oncotarget 2017;8:107730-43. [PMID: 29296201 DOI: 10.18632/oncotarget.22594] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
4 Man KF, Ma S. Mechanisms of resistance to tyrosine kinase inhibitors in liver cancer stem cells and potential therapeutic approaches. Essays Biochem 2022:EBC20220001. [PMID: 35818992 DOI: 10.1042/EBC20220001] [Reference Citation Analysis]
5 Ciaffaglione V, Modica MN, Pittalà V, Romeo G, Salerno L, Intagliata S. Mutual Prodrugs of 5-Fluorouracil: From a Classic Chemotherapeutic Agent to Novel Potential Anticancer Drugs. ChemMedChem 2021. [PMID: 34415107 DOI: 10.1002/cmdc.202100473] [Reference Citation Analysis]
6 Jiang Y, Li X, Hou J, Huang Y, Wang X, Jia Y, Wang Q, Xu W, Zhang J, Zhang Y. Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy. Eur J Med Chem 2018;143:334-47. [PMID: 29202398 DOI: 10.1016/j.ejmech.2017.11.074] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
7 Zhang M, Cai H, Du Y, Wang Y, Gong J, Xu J, Liu X. Enhancing the Therapeutic Efficacy of Gefitinib in Human Non-Small-Cell Lung Cancer through Drug Combination. Mol Pharm 2021;18:1397-407. [PMID: 33471533 DOI: 10.1021/acs.molpharmaceut.0c01203] [Reference Citation Analysis]
8 Ge J, Wang Z, Cheng Y, Ren J, Wu B, Li W, Wang X, Su X, Liu Z. Computational study of novel natural inhibitors targeting aminopeptidase N(CD13). Aging (Albany NY) 2020;12:8523-35. [PMID: 32388498 DOI: 10.18632/aging.103155] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
9 Colvin H, Mori M. Getting to the heart of the matter in cancer: Novel approaches to targeting cancer stem cells. Proc Jpn Acad Ser B Phys Biol Sci 2017;93:146-54. [PMID: 28302961 DOI: 10.2183/pjab.93.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
10 Masoumi J, Jafarzadeh A, Abdolalizadeh J, Khan H, Philippe J, Mirzaei H, Mirzaei HR. Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects. Acta Pharm Sin B 2021;11:1721-39. [PMID: 34386318 DOI: 10.1016/j.apsb.2020.12.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
11 Guo Q, Li X, Cui MN, Sun JL, Ji HY, Ni BB, Yan MX. CD13: A Key Player in Multidrug Resistance in Cancer Chemotherapy. Oncol Res 2020;28:533-40. [PMID: 32532363 DOI: 10.3727/096504020X15919605976853] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Otsuki T, Nakashima T, Hamada H, Takayama Y, Akita S, Masuda T, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Miyake M, Kohno N, Okada M, Hattori N. Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma. Eur Respir J 2018;51:1701610. [PMID: 29519924 DOI: 10.1183/13993003.01610-2017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
13 He X, Hu Y, Shi W, Li X, Ma H. Design, synthesis and application of a near-infrared fluorescent probe for in vivo imaging of aminopeptidase N. Chem Commun 2017;53:9438-41. [DOI: 10.1039/c7cc05142e] [Cited by in Crossref: 40] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
14 Xiao Y, Lin M, Jiang X, Ye J, Guo T, Shi Y, Bian X. The Recent Advances on Liver Cancer Stem Cells: Biomarkers, Separation, and Therapy. Anal Cell Pathol (Amst) 2017;2017:5108653. [PMID: 28819584 DOI: 10.1155/2017/5108653] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
15 Sibuh BZ, Gahtori R, Al-Dayan N, Pant K, Far BF, Malik AA, Gupta AK, Sadhu S, Dohare S, Gupta PK. Emerging trends in immunotoxin targeting cancer stem cells. Toxicol In Vitro 2022;83:105417. [PMID: 35718257 DOI: 10.1016/j.tiv.2022.105417] [Reference Citation Analysis]
16 Cao J, Zang J, Kong X, Zhao C, Chen T, Ran Y, Dong H, Xu W, Zhang Y. Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II. Bioorg Med Chem 2019;27:978-90. [PMID: 30737134 DOI: 10.1016/j.bmc.2019.01.041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
17 Wang K, Sun D. Cancer stem cells of hepatocellular carcinoma. Oncotarget 2018;9:23306-14. [PMID: 29796190 DOI: 10.18632/oncotarget.24623] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
18 Zhang J, Fang C, Qu M, Wu H, Wang X, Zhang H, Ma H, Zhang Z, Huang Y, Shi L, Liang S, Gao Z, Song W, Wang X. CD13 Inhibition Enhances Cytotoxic Effect of Chemotherapy Agents. Front Pharmacol 2018;9:1042. [PMID: 30258365 DOI: 10.3389/fphar.2018.01042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
19 Sukowati CHC, El-Khobar KE, Tiribelli C. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World J Stem Cells 2021; 13(7): 795-824 [PMID: 34367478 DOI: 10.4252/wjsc.v13.i7.795] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Wang Y, Wang J, Yang L, Qiu L, Hua Y, Wu S, Zeng S, Yu L, Zheng X. Epigenetic regulation of intestinal peptide transporter PEPT1 as a potential strategy for colorectal cancer sensitization. Cell Death Dis 2021;12:532. [PMID: 34031358 DOI: 10.1038/s41419-021-03814-5] [Reference Citation Analysis]
21 Sahoo DK, Borcherding DC, Chandra L, Jergens AE, Atherly T, Bourgois-mochel A, Ellinwood NM, Snella E, Severin AJ, Martin M, Allenspach K, Mochel JP. Differential Transcriptomic Profiles Following Stimulation with Lipopolysaccharide in Intestinal Organoids from Dogs with Inflammatory Bowel Disease and Intestinal Mast Cell Tumor. Cancers 2022;14:3525. [DOI: 10.3390/cancers14143525] [Reference Citation Analysis]
22 Wang X, Liu Y, Liu W, Zhang Y, Guo F, Zhang L, Cui M, Liu S, Wu R. Ubenimex, an APN inhibitor, could serve as an anti‑tumor drug in RT112 and 5637 cells by operating in an Akt‑associated manner. Mol Med Rep 2018;17:4531-9. [PMID: 29328441 DOI: 10.3892/mmr.2018.8402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
23 Tsai SC, Lin CC, Shih TC, Tseng RJ, Yu MC, Lin YJ, Hsieh SY. The miR-200b-ZEB1 circuit regulates diverse stemness of human hepatocellular carcinoma. Mol Carcinog 2017;56:2035-47. [PMID: 28383782 DOI: 10.1002/mc.22657] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
24 Yousef EH, El-Mesery ME, Habeeb MR, Eissa LA. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma. Tumour Biol 2020;42:1010428320914475. [PMID: 32252611 DOI: 10.1177/1010428320914475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Mokhtarzadeh A, Hassanpour S, Vahid ZF, Hejazi M, Hashemi M, Ranjbari J, Tabarzad M, Noorolyai S, de la Guardia M. Nano-delivery system targeting to cancer stem cell cluster of differentiation biomarkers. J Control Release 2017;266:166-86. [PMID: 28941992 DOI: 10.1016/j.jconrel.2017.09.028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
26 Schulte LA, López-Gil JC, Sainz B Jr, Hermann PC. The Cancer Stem Cell in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E684. [PMID: 32183251 DOI: 10.3390/cancers12030684] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
27 Zhao Y, Wu H, Xing X, Ma Y, Ji S, Xu X, Zhao X, Wang S, Jiang W, Fang C, Zhang L, Yan F, Wang X. CD13 Induces Autophagy to Promote Hepatocellular Carcinoma Cell Chemoresistance Through the P38/Hsp27/CREB/ATG7 Pathway. J Pharmacol Exp Ther 2020;374:512-20. [PMID: 32571958 DOI: 10.1124/jpet.120.265637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Yue K, Hou X, Jia G, Zhang L, Zhang J, Tan L, Wang X, Zhang Z, Li P, Xu W, Li X, Jiang Y. Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy. Bioorg Chem 2021;116:105343. [PMID: 34544027 DOI: 10.1016/j.bioorg.2021.105343] [Reference Citation Analysis]
29 Wang Y, Pang B, Zhang R, Fu Y, Pang Q. Ubenimex induces apoptotic and autophagic cell death in rat GH3 and MMQ cells through the ROS/ERK pathway. Drug Des Devel Ther 2019;13:3217-28. [PMID: 31571825 DOI: 10.2147/DDDT.S218371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
30 Hou XL, Dai X, Yang J, Zhang B, Zhao DH, Li CQ, Yin ZY, Zhao YD, Liu B. Injectable polypeptide-engineered hydrogel depot for amplifying the anti-tumor immune effect induced by chemo-photothermal therapy. J Mater Chem B 2020;8:8623-33. [PMID: 32821893 DOI: 10.1039/d0tb01370f] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
31 Zhao J, Fu Y, Wu J, Li J, Huang G, Qin L. The Diverse Mechanisms of miRNAs and lncRNAs in the Maintenance of Liver Cancer Stem Cells. Biomed Res Int 2018;2018:8686027. [PMID: 29888282 DOI: 10.1155/2018/8686027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
32 Toshiyama R, Konno M, Eguchi H, Takemoto H, Noda T, Asai A, Koseki J, Haraguchi N, Ueda Y, Matsushita K, Asukai K, Ohashi T, Iwagami Y, Yamada D, Sakai D, Asaoka T, Kudo T, Kawamoto K, Gotoh K, Kobayashi S, Satoh T, Doki Y, Nishiyama N, Mori M, Ishii H. Poly(ethylene glycol)-poly(lysine) block copolymer-ubenimex conjugate targets aminopeptidase N and exerts an antitumor effect in hepatocellular carcinoma stem cells. Oncogene 2019;38:244-60. [PMID: 30089817 DOI: 10.1038/s41388-018-0406-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
33 Miao H, Chen X, Luan Y. Small Molecular Gemcitabine Prodrugs for Cancer Therapy. Curr Med Chem 2020;27:5562-82. [PMID: 31419928 DOI: 10.2174/0929867326666190816230650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Osana S, Kitajima Y, Suzuki N, Xu Y, Murayama K, Nagatomi R. siRNA knockdown of alanine aminopeptidase impairs myoblast proliferation and differentiation. Exp Cell Res 2020;397:112337. [PMID: 33091420 DOI: 10.1016/j.yexcr.2020.112337] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Hu B, Xu Y, Li YC, Huang JF, Cheng JW, Guo W, Yin Y, Gao Y, Wang PX, Wu SY, Zhou J, Fan J, Yang XR. CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-κB oncogenic signaling. Clin Transl Med 2020;10:e233. [PMID: 33377659 DOI: 10.1002/ctm2.233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]